AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise

AN2 Therapeutics Announces Voluntary Pause in Enrollment for Epetraborole Clinical Trial

AN2 Therapeutics, a biopharmaceutical company focused on developing innovative treatments for serious infectious diseases, has announced a voluntary pause in the enrollment of its Phase 2/3 clinical trial for epetraborole, a potential treatment for MAC lung disease. The decision to pause enrollment was based on a blinded aggregate analysis of the ongoing Phase 2 study, which indicated potentially lower efficacy than anticipated. Safety concerns were not a factor in this decision.